Skip to main content
Equibles
ARTL logo

ARTL · Artelo Biosciences, Inc. · Investor Relations

Track ARTL — free

Use ARTL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ARTL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.56 -0.06 (-2.29%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.”
View the 10-Q filed Aug 12, 2026
Market Cap
$1.37M
Shares
510,563
Volume · Oct 21 17.38K Avg daily vol (37 sessions) 789.99K

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Past events

Date Event Type
2026-10-07 Artelo Biosciences Selected for its First-Ever Company Presentation at BIO-Europe 2026 to Showcase Clinical Progress and Expanding Potential of its Novel FABP5 Inhibitor Platform Presentation
2026-09-23 Artelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical Findings Event
2026-09-16 Artelo Biosciences Announces ART27.13 Achieved Weight Loss Comparable to Semaglutide as a Monotherapy and Doubled Weight Loss in Combination with Semaglutide in a Nonclinical Model of Obesity Event
2026-09-11 H.C. Wainwright 28th Annual Global Investment Conference Conference
2026-09-08 Artelo Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference Conference
2026-09-01 Investor Presentation - September 2026 Presentation
2026-08-27 Artelo Biosciences Announces Reverse Stock Split Event
2026-08-20 Artelo Biosciences Secures Notice of Allowance in Japan for Patent Claims for the Intended Commercial Formulation of ART27.13 Event
2026-08-17 Artelo Biosciences Receives a Notice of Allowance from the U.S. Patent and Trademark Office for its Lead Investigational Drug Currently in Two Phase 2 Studies Event
2026-08-17 Investor Presentation - August 2026 Presentation
2026-08-13 Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results Results publication
2026-08-10 Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma Event
2026-07-22 New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition Event
2026-07-17 2026 Annual Meeting of Stockholders Shareholder meeting
2026-07-16 Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions Event
2026-07-14 Artelo Biosciences Issues Reminder to Shareholders to Vote in Advance of Annual Meeting on July 17, 2026 Shareholder meeting
2026-07-13 Artelo Biosciences Announces Positive Results with ART27.13 in a Nonclinical Model of Paclitaxel-Induced Peripheral Neuropathy Event
2026-07-01 Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury Event
2026-06-30 Artelo Biosciences Presents Evidence for a Common Lipid-Signaling Link Across Multiple Potential Indications for Its FABP5 Inhibitor Platform at ICRS 2026 Event
2026-06-29 Artelo Biosciences Presents Clinical and Biomarker Data Supportive of the Development of ART26.12 and Follow-On FABP5 Inhibitors at ICRS 2026 Event
2026-06-10 Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success Event
2026-06-01 Investor Presentation - June 2026 Presentation
2026-05-14 Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results Results publication

Source: https://artelobio.com/investors/

Key facts CIK 1621221 CUSIP 04301G805 13F (30d) 1 filings 1 filers Visit website Investor relations